This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
PEACE-3 Trial
PROfound Trial
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
VISION Trial
mHSPC
ARANOTE Trial
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
COBRA Trial
CONDOR Trial
OSPREY Trial
Bladder Cancer
ANKTIVA®
Bladder Cancer Detection
CORE-001 Study
EV-302
Immunotherapy in NMIBC
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Shilpa Gupta, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Jaime Landman, MD
Prostate Cancer
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
Decipher® Genomic Classifier
Imaging Center
Phillip Koo, MD
mHSPC
Neeraj Agarwal, FASCO, MD
nmCRPC
Zachary Klaassen, MD, MSc
mCRPC Treatment
A. Oliver Sartor, MD
mCRPC with Bone Metastasis
PSMA-Targeted Therapy
Advanced Prostate Cancer
Zachary Klaassen, MD, MSc
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular Cancer
Pelvic Health & Reconstruction
Bladder Health
Urologic Catheters (Includes CAUTI)
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Practice Guidelines Reviews
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Actionable Clinical Data
Bladder Cancer
LG-IR NMIBC
Adstiladrin®
Kidney Cancer
ZIRCON
Trials in Progress
Trials in Progress
Bladder Cancer
BOND-003 Cohort P
CORE-008
IMMORTAL
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
CLARIFY
ECLIPSE
ESCAPE
FORT
Right Side
Prostate Cancer
METANOVA
NRG-GU 0101
PROMISE
RTIRE
SECuRE
SHORTER
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
AUA 2025
PSMA and Beyond 2025 Conference
EAU 2025
SES AUA 2025
Thought Leaders 2025
All Conferences
View All
Quick Takes
ESMO 2024
PCF
UroToday Home
Video Lectures
ASCO 2021
ASCO 2021 VL
Search
Clear
Most recent
Most hits
Most likes
Most dislikes
Title alphabetical
Recently modified
Recently viewed
Author alphabetical
Random
10
20
30
40
50
Determining Dose-Limiting Toxicity and Maximum Tolerated Dose of 225Ac-J591 in Metastatic Castration-Resistant Prostate Cancer - Scott Tagawa
Details
Scott Tagawa joins Alicia Morgans in a discussion on a Phase I study evaluating the tolerability of 225Ac-J591 in metastatic castration-resistant prostate cancer (mCRPC). This study was designed to determine the dose-limiting toxicity and the maximum tolerated dose of 225Ac-J591 in a single dose regimen of 225Ac-J591 that can be given without severe side effects. The initial dose-escalation portio...
Feasibility of Neoadjuvant Nivolumab Without or With Lirilumab for Muscle-Invasive Bladder Cancer (PrE0807) – Petros Grivas
Details
In this conversation with Alicia Morgans, MD, MPH, Petros Grivas, MD, PhD highlights the PrE0807 phase Ib feasibility trial of neoadjuvant nivolumab without or with lirilumab in cisplatin-ineligible patients with muscle-invasive bladder cancer (MIBC). Neoadjuvant cisplatin-based chemotherapy prior to radical cystectomy has been found to improve overall survival in MIBC, but about half of patients...
The Optimal Timing for Starting Avelumab Maintenance After Completing First-line Chemotherapy, JAVELIN Bladder 100 - Srikala Sridhar
Details
The phase 3 JAVELIN Bladder 100 trial demonstrated that First-line maintenance therapy with avelumab + best supportive care (BSC) significantly prolonged overall survival (OS) compared with BSC alone, while the optimal timing for starting avelumab after completing first-line (1L) chemotherapy is still unknown. In a presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meetin...
Patient Preference Study Evaluating Darolutamide and Enzalutamide in Men with mCRPC - Karim Fizazi
Details
In this conversation with Alicia Morgans, MD, MPH, Karim Fizazi shares trial results from the phase II ODENZA trial presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting. ODENZA is a French prospective, randomized, open-label, multicenter, cross-over phase II trial of preference between darolutamide and enzalutamide in men with asymptomatic or mildly symptomatic metasta...
Real-World Data Demonstrates Limited Treatment Intensification for Metastatic Castration-Sensitive Prostate Cancer (mCSPC) and Disparities by Race - Stephen Freedland
Details
Stephen Freedland, MD, joins Alicia Morgans, MD, MPH, to discuss a retrospective analysis of the Medicare database from January 2009-Dec 2018 on the real-world use of advanced therapies over time and the use of patterns among racial minorities that are often under-represented in clinical trials. These data were presented at the ASCO 2021 Annual Meeting. The researchers examined 35,195 patients in...
Apalutamide Improves Overall Survival and rPFS While Preserving Health-Related Quality of Life in Metastatic Castration-Sensitive Prostate Cancer (mCSPC) - Neeraj Agarwal
Details
The TITAN Study is the pivotal phase III trial demonstrating the benefit of apalutamide in mHSPC. At the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, Neeraj Agarwal, MD, presented the health-related quality of life (HRQoL) data from this final analysis after cross-over from the phase III TITAN trial. In this conversation with Alicia Morgans, MD, MPH, he highlights this data. T...
Start
Prev
1
2
3
4
5
Next
End
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free